Publication

Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH

Clinical and Translational Science 15(5):1167-1186, 2022 Møllerhøj MB, Veidal SS, Thrane KT, Oró D, Overgaard A, Salinas CG, Madsen MR, Pfisterer L, Vyberg M, Simon E, Broermann A, Vrang N, Jelsing J, Feigh M, Hansen HH

 

  • GAN DIO-MASH model is top-ranked by the LITMUS consortium: read more
Subjects
GAN DIO-NASH (GAN DIO-MASH) mouseTherapeutic AreaGAN DIO-NASH-HCC (GAN DIO-MASH-HCC) mouseTargetMouseCompoundMethod/EndpointSpeciesBody weightBlood biochemistryHepatocellular carcinoma (HCC)BioinformaticsNon-alcoholic steatohepatitis/Metabolic dysfunction-associated steatohepatitis (NASH/MASH)Dietary interventionGLP-1 receptorHistopathology scoreImage analysisImmunohistochemistryLiver biopsyLiver morphometryPPARLanifibranorReal-time food intake/activity analysisRNA sequencingSemaglutide

Share this page

Resource Library

Related resources
Poster
Preclinical efficacy and clinical translatability of lanifibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH 
Poster
Metabolic, biochemical, histopathological, and transcriptomic effects of Seladelpar in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
Poster
Reproducibility of therapeutic effects of resmetirom in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
Webinar
New insights into disease progression and human translatability of the GAN DIO-NASH mouse

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top